Back to Authors

Olencki, Thomas

A5063621818 | I2802841970

Mayo Clinic

The Ohio State University Wexner Medical Center

Citations 2

The RegiSONIC disease registry: Preliminary effectiveness and safety in the first 66 newly diagnosed locally advanced basal cell carcinoma (BCC) patients treated with vismodegib.

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 9023-9023

10.1200/jco.2015.33.15_suppl.9023

Determination of locally advanced basal cell carcinoma (BCC) in the first 285 patients enrolled in the RegiSONIC disease registry study.

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 9022-9022

10.1200/jco.2015.33.15_suppl.9022